Toshihiko Kaneda

Hirakata, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002).

Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002).

Journal: Japanese journal of clinical oncology

Published: May 30, 2024

Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).

Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 03, 2022

Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer.

Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer.

Journal: BMC cancer

Published: October 31, 2021

A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer.

A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer.

Journal: Anticancer research

Published: April 04, 2020

A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.

A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.

Journal: Oncology

Published: June 12, 2019

Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report.

Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report.

Journal: Molecular and clinical oncology

Published: October 19, 2018

Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?

Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?

Journal: Oncotarget

Published: August 12, 2018

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer.

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer.

Journal: Oncotarget

Published: June 11, 2018

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).

Journal: Cancer

Published: April 11, 2018

A statistical issue regarding the original paper by M. Tamiya and others (Med Oncol (2016) 33:2 DOI 10.1007/s12032-015-0715-7).

A statistical issue regarding the original paper by M. Tamiya and others (Med Oncol (2016) 33:2 DOI 10.1007/s12032-015-0715-7).

Journal: Medical oncology (Northwood, London, England)

Published: March 20, 2017

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.

Journal: BMC cancer

Published: January 25, 2017

Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).

Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).

Journal: Cancer chemotherapy and pharmacology

Published: December 05, 2016

Showing 1-12 of 21

Last Updated: 09/26/2026